nodes	percent_of_prediction	percent_of_DWPC	metapath
Methysergide—HTR1F—trigeminal nerve—bone cancer	0.108	0.176	CbGeAlD
Methysergide—HTR1B—dura mater—bone cancer	0.103	0.168	CbGeAlD
Methysergide—HTR1D—dura mater—bone cancer	0.0999	0.163	CbGeAlD
Methysergide—HTR1B—trigeminal nerve—bone cancer	0.0444	0.0723	CbGeAlD
Methysergide—HTR1D—trigeminal nerve—bone cancer	0.043	0.07	CbGeAlD
Methysergide—HTR1B—cranial nerve—bone cancer	0.0316	0.0515	CbGeAlD
Methysergide—HTR1D—cranial nerve—bone cancer	0.0306	0.0498	CbGeAlD
Methysergide—HTR7—cranial nerve—bone cancer	0.0244	0.0397	CbGeAlD
Methysergide—HTR2A—trigeminal nerve—bone cancer	0.0213	0.0348	CbGeAlD
Methysergide—HTR2A—cranial nerve—bone cancer	0.0152	0.0248	CbGeAlD
Methysergide—HTR2A—vertebral column—bone cancer	0.0149	0.0243	CbGeAlD
Methysergide—Telangiectasia—Methotrexate—bone cancer	0.0131	0.0441	CcSEcCtD
Methysergide—HTR2A—hindlimb—bone cancer	0.0128	0.0209	CbGeAlD
Methysergide—Gravitational oedema—Epirubicin—bone cancer	0.0118	0.0398	CcSEcCtD
Methysergide—HTR2A—appendage—bone cancer	0.011	0.0179	CbGeAlD
Methysergide—Gravitational oedema—Doxorubicin—bone cancer	0.0109	0.0369	CcSEcCtD
Methysergide—Leg edema—Epirubicin—bone cancer	0.0107	0.0361	CcSEcCtD
Methysergide—Leg edema—Doxorubicin—bone cancer	0.0099	0.0334	CcSEcCtD
Methysergide—Ergonovine—CYP3A4—bone cancer	0.00767	0.28	CrCbGaD
Methysergide—Methylergometrine—CYP3A4—bone cancer	0.0067	0.245	CrCbGaD
Methysergide—HTR1D—connective tissue—bone cancer	0.00632	0.0103	CbGeAlD
Methysergide—Pain—Carboplatin—bone cancer	0.00584	0.0197	CcSEcCtD
Methysergide—Body temperature increased—Carboplatin—bone cancer	0.00539	0.0182	CcSEcCtD
Methysergide—HTR7—connective tissue—bone cancer	0.00503	0.00819	CbGeAlD
Methysergide—Polyuria—Cisplatin—bone cancer	0.00464	0.0157	CcSEcCtD
Methysergide—Lisuride—CYP3A4—bone cancer	0.0045	0.164	CrCbGaD
Methysergide—HTR1B—spinal cord—bone cancer	0.00433	0.00704	CbGeAlD
Methysergide—Ergotamine—CYP3A4—bone cancer	0.00432	0.158	CrCbGaD
Methysergide—Bromocriptine—CYP3A4—bone cancer	0.00417	0.152	CrCbGaD
Methysergide—HTR2C—spinal cord—bone cancer	0.00415	0.00675	CbGeAlD
Methysergide—SIGMAR1—tendon—bone cancer	0.00405	0.00659	CbGeAlD
Methysergide—HTR2B—tendon—bone cancer	0.00404	0.00658	CbGeAlD
Methysergide—Pleural effusion—Methotrexate—bone cancer	0.00402	0.0136	CcSEcCtD
Methysergide—SIGMAR1—bone marrow—bone cancer	0.00392	0.00639	CbGeAlD
Methysergide—SIGMAR1—spinal cord—bone cancer	0.0039	0.00636	CbGeAlD
Methysergide—Pleural effusion—Epirubicin—bone cancer	0.00376	0.0127	CcSEcCtD
Methysergide—Orthostatic hypotension—Cisplatin—bone cancer	0.00372	0.0126	CcSEcCtD
Methysergide—Hyperaesthesia—Epirubicin—bone cancer	0.00367	0.0124	CcSEcCtD
Methysergide—HTR1A—spinal cord—bone cancer	0.00349	0.00568	CbGeAlD
Methysergide—Pleural effusion—Doxorubicin—bone cancer	0.00348	0.0118	CcSEcCtD
Methysergide—HTR7—tendon—bone cancer	0.00346	0.00563	CbGeAlD
Methysergide—Hyperaesthesia—Doxorubicin—bone cancer	0.0034	0.0115	CcSEcCtD
Methysergide—Oliguria—Methotrexate—bone cancer	0.00334	0.0113	CcSEcCtD
Methysergide—HTR7—spinal cord—bone cancer	0.00334	0.00543	CbGeAlD
Methysergide—HTR2A—connective tissue—bone cancer	0.00314	0.00511	CbGeAlD
Methysergide—Oliguria—Epirubicin—bone cancer	0.00313	0.0106	CcSEcCtD
Methysergide—Oliguria—Doxorubicin—bone cancer	0.00289	0.00977	CcSEcCtD
Methysergide—Urine output increased—Methotrexate—bone cancer	0.00278	0.0094	CcSEcCtD
Methysergide—Blood urea increased—Epirubicin—bone cancer	0.00272	0.00919	CcSEcCtD
Methysergide—Flushing—Cisplatin—bone cancer	0.00261	0.00883	CcSEcCtD
Methysergide—Thrombophlebitis—Methotrexate—bone cancer	0.00258	0.00872	CcSEcCtD
Methysergide—Polyuria—Methotrexate—bone cancer	0.00255	0.0086	CcSEcCtD
Methysergide—Blood urea increased—Doxorubicin—bone cancer	0.00252	0.0085	CcSEcCtD
Methysergide—Alopecia—Cisplatin—bone cancer	0.00249	0.00841	CcSEcCtD
Methysergide—Thrombophlebitis—Epirubicin—bone cancer	0.00242	0.00816	CcSEcCtD
Methysergide—Ill-defined disorder—Cisplatin—bone cancer	0.00228	0.00768	CcSEcCtD
Methysergide—Thrombophlebitis—Doxorubicin—bone cancer	0.00224	0.00755	CcSEcCtD
Methysergide—Malaise—Cisplatin—bone cancer	0.00221	0.00747	CcSEcCtD
Methysergide—HTR2A—tendon—bone cancer	0.00216	0.00351	CbGeAlD
Methysergide—Convulsion—Cisplatin—bone cancer	0.00213	0.00718	CcSEcCtD
Methysergide—Ataxia—Methotrexate—bone cancer	0.0021	0.0071	CcSEcCtD
Methysergide—Pain in extremity—Epirubicin—bone cancer	0.00209	0.00706	CcSEcCtD
Methysergide—Myalgia—Cisplatin—bone cancer	0.00209	0.00705	CcSEcCtD
Methysergide—HTR2A—spinal cord—bone cancer	0.00208	0.00339	CbGeAlD
Methysergide—Discomfort—Cisplatin—bone cancer	0.00206	0.00697	CcSEcCtD
Methysergide—Oedema—Cisplatin—bone cancer	0.002	0.00676	CcSEcCtD
Methysergide—Ataxia—Epirubicin—bone cancer	0.00197	0.00664	CcSEcCtD
Methysergide—Thrombocytopenia—Cisplatin—bone cancer	0.00196	0.00662	CcSEcCtD
Methysergide—Tachycardia—Cisplatin—bone cancer	0.00195	0.0066	CcSEcCtD
Methysergide—Pain in extremity—Doxorubicin—bone cancer	0.00194	0.00654	CcSEcCtD
Methysergide—Eosinophilia—Methotrexate—bone cancer	0.00191	0.00646	CcSEcCtD
Methysergide—Orthostatic hypotension—Epirubicin—bone cancer	0.00191	0.00645	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00182	0.00616	CcSEcCtD
Methysergide—Ataxia—Doxorubicin—bone cancer	0.00182	0.00614	CcSEcCtD
Methysergide—Neutropenia—Methotrexate—bone cancer	0.00181	0.0061	CcSEcCtD
Methysergide—Dysuria—Methotrexate—bone cancer	0.00181	0.0061	CcSEcCtD
Methysergide—Paraesthesia—Cisplatin—bone cancer	0.0018	0.00607	CcSEcCtD
Methysergide—Eosinophilia—Epirubicin—bone cancer	0.00179	0.00604	CcSEcCtD
Methysergide—Dyspnoea—Cisplatin—bone cancer	0.00178	0.00603	CcSEcCtD
Methysergide—Orthostatic hypotension—Doxorubicin—bone cancer	0.00177	0.00597	CcSEcCtD
Methysergide—Gastrointestinal disorder—Cisplatin—bone cancer	0.00173	0.00584	CcSEcCtD
Methysergide—Drowsiness—Methotrexate—bone cancer	0.00172	0.00582	CcSEcCtD
Methysergide—Pain—Cisplatin—bone cancer	0.00171	0.00578	CcSEcCtD
Methysergide—Neutropenia—Epirubicin—bone cancer	0.00169	0.00571	CcSEcCtD
Methysergide—Dysuria—Epirubicin—bone cancer	0.00169	0.00571	CcSEcCtD
Methysergide—Eosinophilia—Doxorubicin—bone cancer	0.00166	0.00559	CcSEcCtD
Methysergide—Feeling abnormal—Cisplatin—bone cancer	0.00165	0.00557	CcSEcCtD
Methysergide—Weight increased—Epirubicin—bone cancer	0.00165	0.00556	CcSEcCtD
Methysergide—Weight decreased—Epirubicin—bone cancer	0.00164	0.00552	CcSEcCtD
Methysergide—Drowsiness—Epirubicin—bone cancer	0.00161	0.00544	CcSEcCtD
Methysergide—Body temperature increased—Cisplatin—bone cancer	0.00158	0.00534	CcSEcCtD
Methysergide—Neutropenia—Doxorubicin—bone cancer	0.00156	0.00528	CcSEcCtD
Methysergide—Dysuria—Doxorubicin—bone cancer	0.00156	0.00528	CcSEcCtD
Methysergide—Weight increased—Doxorubicin—bone cancer	0.00152	0.00514	CcSEcCtD
Methysergide—Weight decreased—Doxorubicin—bone cancer	0.00151	0.00511	CcSEcCtD
Methysergide—Drowsiness—Doxorubicin—bone cancer	0.00149	0.00504	CcSEcCtD
Methysergide—Asthenia—Cisplatin—bone cancer	0.00144	0.00485	CcSEcCtD
Methysergide—Oedema peripheral—Epirubicin—bone cancer	0.00143	0.00481	CcSEcCtD
Methysergide—Diarrhoea—Cisplatin—bone cancer	0.00137	0.00463	CcSEcCtD
Methysergide—Alopecia—Methotrexate—bone cancer	0.00137	0.00461	CcSEcCtD
Methysergide—Flushing—Epirubicin—bone cancer	0.00134	0.00453	CcSEcCtD
Methysergide—Oedema peripheral—Doxorubicin—bone cancer	0.00132	0.00445	CcSEcCtD
Methysergide—Back pain—Methotrexate—bone cancer	0.0013	0.0044	CcSEcCtD
Methysergide—Alopecia—Epirubicin—bone cancer	0.00128	0.00432	CcSEcCtD
Methysergide—Vomiting—Cisplatin—bone cancer	0.00127	0.0043	CcSEcCtD
Methysergide—Rash—Cisplatin—bone cancer	0.00126	0.00426	CcSEcCtD
Methysergide—Dermatitis—Cisplatin—bone cancer	0.00126	0.00426	CcSEcCtD
Methysergide—Ill-defined disorder—Methotrexate—bone cancer	0.00125	0.00422	CcSEcCtD
Methysergide—Flushing—Doxorubicin—bone cancer	0.00124	0.0042	CcSEcCtD
Methysergide—Back pain—Epirubicin—bone cancer	0.00122	0.00411	CcSEcCtD
Methysergide—Malaise—Methotrexate—bone cancer	0.00121	0.0041	CcSEcCtD
Methysergide—Nausea—Cisplatin—bone cancer	0.00119	0.00402	CcSEcCtD
Methysergide—Alopecia—Doxorubicin—bone cancer	0.00118	0.00399	CcSEcCtD
Methysergide—Ill-defined disorder—Epirubicin—bone cancer	0.00117	0.00395	CcSEcCtD
Methysergide—Convulsion—Methotrexate—bone cancer	0.00117	0.00394	CcSEcCtD
Methysergide—Myalgia—Methotrexate—bone cancer	0.00115	0.00387	CcSEcCtD
Methysergide—Arthralgia—Methotrexate—bone cancer	0.00115	0.00387	CcSEcCtD
Methysergide—Chest pain—Methotrexate—bone cancer	0.00115	0.00387	CcSEcCtD
Methysergide—Malaise—Epirubicin—bone cancer	0.00114	0.00384	CcSEcCtD
Methysergide—Discomfort—Methotrexate—bone cancer	0.00113	0.00382	CcSEcCtD
Methysergide—Back pain—Doxorubicin—bone cancer	0.00113	0.00381	CcSEcCtD
Methysergide—Convulsion—Epirubicin—bone cancer	0.00109	0.00369	CcSEcCtD
Methysergide—Ill-defined disorder—Doxorubicin—bone cancer	0.00108	0.00365	CcSEcCtD
Methysergide—Thrombocytopenia—Methotrexate—bone cancer	0.00108	0.00363	CcSEcCtD
Methysergide—Myalgia—Epirubicin—bone cancer	0.00107	0.00362	CcSEcCtD
Methysergide—Chest pain—Epirubicin—bone cancer	0.00107	0.00362	CcSEcCtD
Methysergide—Arthralgia—Epirubicin—bone cancer	0.00107	0.00362	CcSEcCtD
Methysergide—Discomfort—Epirubicin—bone cancer	0.00106	0.00358	CcSEcCtD
Methysergide—Malaise—Doxorubicin—bone cancer	0.00105	0.00355	CcSEcCtD
Methysergide—Oedema—Epirubicin—bone cancer	0.00103	0.00347	CcSEcCtD
Methysergide—Convulsion—Doxorubicin—bone cancer	0.00101	0.00341	CcSEcCtD
Methysergide—Thrombocytopenia—Epirubicin—bone cancer	0.00101	0.0034	CcSEcCtD
Methysergide—Tachycardia—Epirubicin—bone cancer	0.001	0.00339	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Methotrexate—bone cancer	0.001	0.00338	CcSEcCtD
Methysergide—Insomnia—Methotrexate—bone cancer	0.000993	0.00335	CcSEcCtD
Methysergide—Myalgia—Doxorubicin—bone cancer	0.000992	0.00335	CcSEcCtD
Methysergide—Chest pain—Doxorubicin—bone cancer	0.000992	0.00335	CcSEcCtD
Methysergide—Arthralgia—Doxorubicin—bone cancer	0.000992	0.00335	CcSEcCtD
Methysergide—Paraesthesia—Methotrexate—bone cancer	0.000986	0.00333	CcSEcCtD
Methysergide—Discomfort—Doxorubicin—bone cancer	0.00098	0.00331	CcSEcCtD
Methysergide—Dyspnoea—Methotrexate—bone cancer	0.000979	0.00331	CcSEcCtD
Methysergide—Somnolence—Methotrexate—bone cancer	0.000977	0.0033	CcSEcCtD
Methysergide—Dyspepsia—Methotrexate—bone cancer	0.000967	0.00327	CcSEcCtD
Methysergide—Oedema—Doxorubicin—bone cancer	0.000951	0.00321	CcSEcCtD
Methysergide—Gastrointestinal disorder—Methotrexate—bone cancer	0.000948	0.0032	CcSEcCtD
Methysergide—Fatigue—Methotrexate—bone cancer	0.000947	0.0032	CcSEcCtD
Methysergide—Pain—Methotrexate—bone cancer	0.000939	0.00317	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000937	0.00316	CcSEcCtD
Methysergide—Thrombocytopenia—Doxorubicin—bone cancer	0.000931	0.00314	CcSEcCtD
Methysergide—Insomnia—Epirubicin—bone cancer	0.00093	0.00314	CcSEcCtD
Methysergide—Tachycardia—Doxorubicin—bone cancer	0.000928	0.00313	CcSEcCtD
Methysergide—Paraesthesia—Epirubicin—bone cancer	0.000923	0.00312	CcSEcCtD
Methysergide—Dyspnoea—Epirubicin—bone cancer	0.000916	0.00309	CcSEcCtD
Methysergide—Somnolence—Epirubicin—bone cancer	0.000914	0.00309	CcSEcCtD
Methysergide—Feeling abnormal—Methotrexate—bone cancer	0.000905	0.00306	CcSEcCtD
Methysergide—Dyspepsia—Epirubicin—bone cancer	0.000905	0.00306	CcSEcCtD
Methysergide—Gastrointestinal pain—Methotrexate—bone cancer	0.000898	0.00303	CcSEcCtD
Methysergide—Gastrointestinal disorder—Epirubicin—bone cancer	0.000887	0.003	CcSEcCtD
Methysergide—Fatigue—Epirubicin—bone cancer	0.000886	0.00299	CcSEcCtD
Methysergide—Constipation—Epirubicin—bone cancer	0.000879	0.00297	CcSEcCtD
Methysergide—Pain—Epirubicin—bone cancer	0.000879	0.00297	CcSEcCtD
Methysergide—Abdominal pain—Methotrexate—bone cancer	0.000868	0.00293	CcSEcCtD
Methysergide—Body temperature increased—Methotrexate—bone cancer	0.000868	0.00293	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000867	0.00293	CcSEcCtD
Methysergide—Insomnia—Doxorubicin—bone cancer	0.00086	0.00291	CcSEcCtD
Methysergide—Paraesthesia—Doxorubicin—bone cancer	0.000854	0.00288	CcSEcCtD
Methysergide—Dyspnoea—Doxorubicin—bone cancer	0.000848	0.00286	CcSEcCtD
Methysergide—Feeling abnormal—Epirubicin—bone cancer	0.000847	0.00286	CcSEcCtD
Methysergide—Somnolence—Doxorubicin—bone cancer	0.000846	0.00286	CcSEcCtD
Methysergide—Gastrointestinal pain—Epirubicin—bone cancer	0.000841	0.00284	CcSEcCtD
Methysergide—Dyspepsia—Doxorubicin—bone cancer	0.000837	0.00283	CcSEcCtD
Methysergide—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000821	0.00277	CcSEcCtD
Methysergide—Fatigue—Doxorubicin—bone cancer	0.00082	0.00277	CcSEcCtD
Methysergide—Pain—Doxorubicin—bone cancer	0.000813	0.00275	CcSEcCtD
Methysergide—Constipation—Doxorubicin—bone cancer	0.000813	0.00275	CcSEcCtD
Methysergide—Abdominal pain—Epirubicin—bone cancer	0.000813	0.00274	CcSEcCtD
Methysergide—Body temperature increased—Epirubicin—bone cancer	0.000813	0.00274	CcSEcCtD
Methysergide—Asthenia—Methotrexate—bone cancer	0.000788	0.00266	CcSEcCtD
Methysergide—Feeling abnormal—Doxorubicin—bone cancer	0.000784	0.00265	CcSEcCtD
Methysergide—Gastrointestinal pain—Doxorubicin—bone cancer	0.000778	0.00263	CcSEcCtD
Methysergide—Abdominal pain—Doxorubicin—bone cancer	0.000752	0.00254	CcSEcCtD
Methysergide—Body temperature increased—Doxorubicin—bone cancer	0.000752	0.00254	CcSEcCtD
Methysergide—Diarrhoea—Methotrexate—bone cancer	0.000752	0.00254	CcSEcCtD
Methysergide—Asthenia—Epirubicin—bone cancer	0.000738	0.00249	CcSEcCtD
Methysergide—Dizziness—Methotrexate—bone cancer	0.000726	0.00245	CcSEcCtD
Methysergide—Diarrhoea—Epirubicin—bone cancer	0.000703	0.00238	CcSEcCtD
Methysergide—Vomiting—Methotrexate—bone cancer	0.000698	0.00236	CcSEcCtD
Methysergide—Rash—Methotrexate—bone cancer	0.000693	0.00234	CcSEcCtD
Methysergide—Dermatitis—Methotrexate—bone cancer	0.000692	0.00234	CcSEcCtD
Methysergide—Asthenia—Doxorubicin—bone cancer	0.000682	0.0023	CcSEcCtD
Methysergide—Dizziness—Epirubicin—bone cancer	0.00068	0.0023	CcSEcCtD
Methysergide—Vomiting—Epirubicin—bone cancer	0.000654	0.00221	CcSEcCtD
Methysergide—Nausea—Methotrexate—bone cancer	0.000652	0.0022	CcSEcCtD
Methysergide—Diarrhoea—Doxorubicin—bone cancer	0.000651	0.0022	CcSEcCtD
Methysergide—Rash—Epirubicin—bone cancer	0.000648	0.00219	CcSEcCtD
Methysergide—Dermatitis—Epirubicin—bone cancer	0.000648	0.00219	CcSEcCtD
Methysergide—Dizziness—Doxorubicin—bone cancer	0.000629	0.00212	CcSEcCtD
Methysergide—Nausea—Epirubicin—bone cancer	0.000611	0.00206	CcSEcCtD
Methysergide—Vomiting—Doxorubicin—bone cancer	0.000605	0.00204	CcSEcCtD
Methysergide—Rash—Doxorubicin—bone cancer	0.0006	0.00203	CcSEcCtD
Methysergide—Dermatitis—Doxorubicin—bone cancer	0.000599	0.00202	CcSEcCtD
Methysergide—Nausea—Doxorubicin—bone cancer	0.000565	0.00191	CcSEcCtD
Methysergide—HTR1E—GPCR downstream signaling—GNA11—bone cancer	0.000163	0.00261	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—SMO—bone cancer	0.000162	0.00259	CbGpPWpGaD
Methysergide—HTR1A—GPCR ligand binding—SMO—bone cancer	0.00016	0.00256	CbGpPWpGaD
Methysergide—HTR2C—GPCR ligand binding—SMO—bone cancer	0.000159	0.00254	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—GRM1—bone cancer	0.000158	0.00253	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—GRM1—bone cancer	0.000157	0.00252	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—GNA11—bone cancer	0.000157	0.00252	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—GRM1—bone cancer	0.000157	0.00251	CbGpPWpGaD
Methysergide—HTR1F—GPCR downstream signaling—IL3—bone cancer	0.000157	0.00251	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—GRM4—bone cancer	0.000157	0.00251	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—RGS1—bone cancer	0.000157	0.00251	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—GRM1—bone cancer	0.000156	0.0025	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—GRM1—bone cancer	0.000153	0.00244	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—GNA11—bone cancer	0.000148	0.00237	CbGpPWpGaD
Methysergide—HTR1E—GPCR downstream signaling—IL3—bone cancer	0.000148	0.00237	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—RGS1—bone cancer	0.000148	0.00237	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—GRM4—bone cancer	0.000148	0.00237	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—GRM4—bone cancer	0.000147	0.00235	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—RGS1—bone cancer	0.000147	0.00235	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—GRM1—bone cancer	0.000144	0.00231	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—GRM1—bone cancer	0.000143	0.0023	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—IL3—bone cancer	0.000142	0.00228	CbGpPWpGaD
Methysergide—HTR2A—GPCR ligand binding—SMO—bone cancer	0.000138	0.00221	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—GRM1—bone cancer	0.000136	0.00218	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—IL3—bone cancer	0.000134	0.00215	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—RGS1—bone cancer	0.000134	0.00215	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—GRM4—bone cancer	0.000134	0.00215	CbGpPWpGaD
Methysergide—HTR7—Circadian rythm related genes—JUN—bone cancer	0.000134	0.00214	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—GRM4—bone cancer	0.000133	0.00214	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—RGS1—bone cancer	0.000133	0.00214	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—GRM1—bone cancer	0.000128	0.00205	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—RGS1—bone cancer	0.000128	0.00204	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—GRM4—bone cancer	0.000128	0.00204	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—GRM1—bone cancer	0.000127	0.00204	CbGpPWpGaD
Methysergide—HTR1A—SIDS Susceptibility Pathways—JUN—bone cancer	0.000121	0.00194	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—GRM1—bone cancer	0.000116	0.00186	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—RGS1—bone cancer	0.000116	0.00186	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—GRM4—bone cancer	0.000116	0.00186	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—GRM1—bone cancer	0.000116	0.00185	CbGpPWpGaD
Methysergide—HTR6—GPCR downstream signaling—GNA11—bone cancer	0.000112	0.00179	CbGpPWpGaD
Methysergide—HTR7—GPCR downstream signaling—GNA11—bone cancer	0.000111	0.00178	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—SMO—bone cancer	0.000111	0.00177	CbGpPWpGaD
Methysergide—HTR1D—GPCR downstream signaling—GNA11—bone cancer	0.000111	0.00177	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—GRM1—bone cancer	0.000111	0.00177	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—SMO—bone cancer	0.000111	0.00177	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—SMO—bone cancer	0.00011	0.00176	CbGpPWpGaD
Methysergide—HTR1B—GPCR downstream signaling—GNA11—bone cancer	0.000108	0.00173	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—SMO—bone cancer	0.000108	0.00172	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—GRM4—bone cancer	0.000107	0.00171	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—RGS1—bone cancer	0.000107	0.00171	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—GRM4—bone cancer	0.000107	0.00171	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—RGS1—bone cancer	0.000107	0.00171	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—RGS1—bone cancer	0.000106	0.0017	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—GRM4—bone cancer	0.000106	0.0017	CbGpPWpGaD
Methysergide—HTR2A—SIDS Susceptibility Pathways—JUN—bone cancer	0.000105	0.00168	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—GRM4—bone cancer	0.000104	0.00167	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—RGS1—bone cancer	0.000104	0.00167	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—GNA11—bone cancer	0.000102	0.00163	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—SMO—bone cancer	0.000101	0.00162	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—GNA11—bone cancer	0.000101	0.00162	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—GNA11—bone cancer	0.000101	0.00162	CbGpPWpGaD
Methysergide—HTR6—GPCR downstream signaling—IL3—bone cancer	0.000101	0.00162	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—SMO—bone cancer	0.000101	0.00162	CbGpPWpGaD
Methysergide—HTR7—GPCR downstream signaling—IL3—bone cancer	0.000101	0.00162	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—GNA11—bone cancer	0.0001	0.00161	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—GRM1—bone cancer	0.0001	0.00161	CbGpPWpGaD
Methysergide—HTR1D—GPCR downstream signaling—IL3—bone cancer	0.0001	0.00161	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—GNA11—bone cancer	9.84e-05	0.00158	CbGpPWpGaD
Methysergide—HTR1B—GPCR downstream signaling—IL3—bone cancer	9.82e-05	0.00157	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—GRM4—bone cancer	9.77e-05	0.00156	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—RGS1—bone cancer	9.77e-05	0.00156	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—SMO—bone cancer	9.57e-05	0.00153	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—GRM1—bone cancer	9.28e-05	0.00149	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—GNA11—bone cancer	9.28e-05	0.00149	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—GRM1—bone cancer	9.27e-05	0.00148	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—GNA11—bone cancer	9.24e-05	0.00148	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—IL3—bone cancer	9.23e-05	0.00148	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—GRM1—bone cancer	9.21e-05	0.00147	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—IL3—bone cancer	9.18e-05	0.00147	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—IL3—bone cancer	9.17e-05	0.00147	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—IL3—bone cancer	9.11e-05	0.00146	CbGpPWpGaD
Methysergide—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	9.1e-05	0.00146	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—GRM1—bone cancer	9.02e-05	0.00144	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—IL3—bone cancer	8.92e-05	0.00143	CbGpPWpGaD
Methysergide—HTR7—Circadian rythm related genes—TP53—bone cancer	8.82e-05	0.00141	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—GNA11—bone cancer	8.76e-05	0.0014	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—ATF1—bone cancer	8.63e-05	0.00138	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—GRM1—bone cancer	8.47e-05	0.00136	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—IL3—bone cancer	8.42e-05	0.00135	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—IL3—bone cancer	8.38e-05	0.00134	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—GNA11—bone cancer	8.25e-05	0.00132	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—GNA11—bone cancer	8.21e-05	0.00131	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—SMO—bone cancer	8.2e-05	0.00131	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—SMO—bone cancer	8.15e-05	0.00131	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—ATF1—bone cancer	8.14e-05	0.0013	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—IL3—bone cancer	7.94e-05	0.00127	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—GRM4—bone cancer	7.92e-05	0.00127	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—RGS1—bone cancer	7.92e-05	0.00127	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—RGS1—bone cancer	7.88e-05	0.00126	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—GRM4—bone cancer	7.88e-05	0.00126	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—GNA11—bone cancer	7.5e-05	0.0012	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—IL3—bone cancer	7.48e-05	0.0012	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—GNA11—bone cancer	7.46e-05	0.00119	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—IL3—bone cancer	7.44e-05	0.00119	CbGpPWpGaD
Methysergide—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	7.34e-05	0.00117	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—TGFBR2—bone cancer	7.2e-05	0.00115	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—GNA11—bone cancer	7.13e-05	0.00114	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—SMO—bone cancer	7.08e-05	0.00113	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—GRM1—bone cancer	6.87e-05	0.0011	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—GRM4—bone cancer	6.85e-05	0.0011	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—RGS1—bone cancer	6.85e-05	0.0011	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—GRM1—bone cancer	6.84e-05	0.00109	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—IL3—bone cancer	6.8e-05	0.00109	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TGFBR2—bone cancer	6.79e-05	0.00109	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—IGF1R—bone cancer	6.77e-05	0.00108	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—IL3—bone cancer	6.76e-05	0.00108	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—SMO—bone cancer	6.54e-05	0.00105	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—SMO—bone cancer	6.53e-05	0.00105	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—SMO—bone cancer	6.49e-05	0.00104	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—GNA11—bone cancer	6.48e-05	0.00104	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—IL3—bone cancer	6.46e-05	0.00103	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—IGF1R—bone cancer	6.39e-05	0.00102	CbGpPWpGaD
Methysergide—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	6.37e-05	0.00102	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—SMO—bone cancer	6.35e-05	0.00102	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—GNA11—bone cancer	5.98e-05	0.000958	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—GNA11—bone cancer	5.97e-05	0.000957	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—SMO—bone cancer	5.97e-05	0.000956	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—GRM1—bone cancer	5.94e-05	0.00095	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—GNA11—bone cancer	5.94e-05	0.00095	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—IL3—bone cancer	5.87e-05	0.00094	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—GNA11—bone cancer	5.81e-05	0.000931	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—ATF1—bone cancer	5.56e-05	0.00089	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—ATF1—bone cancer	5.55e-05	0.000889	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—ATF1—bone cancer	5.52e-05	0.000883	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—GNA11—bone cancer	5.46e-05	0.000874	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—IL3—bone cancer	5.42e-05	0.000868	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—IL3—bone cancer	5.42e-05	0.000867	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—ATF1—bone cancer	5.4e-05	0.000865	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—IL3—bone cancer	5.38e-05	0.000862	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IL3—bone cancer	5.27e-05	0.000844	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—ATF1—bone cancer	5.08e-05	0.000813	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IL3—bone cancer	4.95e-05	0.000792	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—KIT—bone cancer	4.91e-05	0.000786	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—SMO—bone cancer	4.84e-05	0.000775	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—SMO—bone cancer	4.82e-05	0.000771	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TGFBR2—bone cancer	4.64e-05	0.000743	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—KIT—bone cancer	4.63e-05	0.000742	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TGFBR2—bone cancer	4.63e-05	0.000742	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—BRAF—bone cancer	4.62e-05	0.000739	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TGFBR2—bone cancer	4.6e-05	0.000737	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TGFBR2—bone cancer	4.51e-05	0.000722	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—EGFR—bone cancer	4.47e-05	0.000716	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—GNA11—bone cancer	4.43e-05	0.000709	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—GNA11—bone cancer	4.4e-05	0.000705	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—IGF1R—bone cancer	4.36e-05	0.000699	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—IGF1R—bone cancer	4.36e-05	0.000698	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—BRAF—bone cancer	4.35e-05	0.000697	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—IGF1R—bone cancer	4.33e-05	0.000693	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IGF1R—bone cancer	4.24e-05	0.000679	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TGFBR2—bone cancer	4.23e-05	0.000678	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—EGFR—bone cancer	4.22e-05	0.000676	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SMO—bone cancer	4.18e-05	0.00067	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—ATF1—bone cancer	4.12e-05	0.000659	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—ATF1—bone cancer	4.1e-05	0.000656	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IL3—bone cancer	4.01e-05	0.000643	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IL3—bone cancer	3.99e-05	0.000639	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IGF1R—bone cancer	3.98e-05	0.000638	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—MDM2—bone cancer	3.87e-05	0.000619	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—GNA11—bone cancer	3.83e-05	0.000612	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—MDM2—bone cancer	3.65e-05	0.000584	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—ATF1—bone cancer	3.56e-05	0.000569	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IL3—bone cancer	3.47e-05	0.000555	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TGFBR2—bone cancer	3.43e-05	0.00055	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TGFBR2—bone cancer	3.42e-05	0.000547	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—JUN—bone cancer	3.36e-05	0.000538	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—MMP9—bone cancer	3.27e-05	0.000524	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IGF1R—bone cancer	3.23e-05	0.000517	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IGF1R—bone cancer	3.21e-05	0.000514	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—JUN—bone cancer	3.17e-05	0.000508	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—KIT—bone cancer	3.16e-05	0.000507	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—KIT—bone cancer	3.16e-05	0.000506	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—KIT—bone cancer	3.14e-05	0.000503	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—MMP9—bone cancer	3.09e-05	0.000494	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—KIT—bone cancer	3.08e-05	0.000492	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—BRAF—bone cancer	2.97e-05	0.000476	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—BRAF—bone cancer	2.97e-05	0.000476	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TGFBR2—bone cancer	2.97e-05	0.000475	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—BRAF—bone cancer	2.95e-05	0.000473	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—BRAF—bone cancer	2.89e-05	0.000463	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—KIT—bone cancer	2.89e-05	0.000462	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—EGFR—bone cancer	2.88e-05	0.000462	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—EGFR—bone cancer	2.88e-05	0.000461	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—EGFR—bone cancer	2.86e-05	0.000458	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—EGFR—bone cancer	2.8e-05	0.000449	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IGF1R—bone cancer	2.79e-05	0.000447	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—BRAF—bone cancer	2.72e-05	0.000435	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—EGFR—bone cancer	2.64e-05	0.000423	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—EGFR—bone cancer	2.63e-05	0.000421	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—EGFR—bone cancer	2.49e-05	0.000399	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MDM2—bone cancer	2.49e-05	0.000399	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MDM2—bone cancer	2.49e-05	0.000399	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MDM2—bone cancer	2.47e-05	0.000396	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MDM2—bone cancer	2.42e-05	0.000388	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—KIT—bone cancer	2.34e-05	0.000375	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—KIT—bone cancer	2.33e-05	0.000373	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MDM2—bone cancer	2.28e-05	0.000364	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—TP53—bone cancer	2.22e-05	0.000355	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—BRAF—bone cancer	2.2e-05	0.000353	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—BRAF—bone cancer	2.19e-05	0.000351	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—JUN—bone cancer	2.17e-05	0.000347	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—JUN—bone cancer	2.16e-05	0.000346	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—JUN—bone cancer	2.15e-05	0.000344	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—EGFR—bone cancer	2.13e-05	0.000342	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—EGFR—bone cancer	2.12e-05	0.00034	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MMP9—bone cancer	2.11e-05	0.000337	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MMP9—bone cancer	2.11e-05	0.000337	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—JUN—bone cancer	2.11e-05	0.000337	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TP53—bone cancer	2.09e-05	0.000335	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MMP9—bone cancer	2.09e-05	0.000335	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MMP9—bone cancer	2.05e-05	0.000328	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—KIT—bone cancer	2.02e-05	0.000324	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—JUN—bone cancer	1.98e-05	0.000317	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MMP9—bone cancer	1.92e-05	0.000308	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—BRAF—bone cancer	1.9e-05	0.000305	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MDM2—bone cancer	1.84e-05	0.000295	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—EGFR—bone cancer	1.84e-05	0.000295	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MDM2—bone cancer	1.84e-05	0.000294	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—EGFR—bone cancer	1.7e-05	0.000273	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—EGFR—bone cancer	1.7e-05	0.000272	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—EGFR—bone cancer	1.69e-05	0.000271	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—EGFR—bone cancer	1.66e-05	0.000265	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—JUN—bone cancer	1.6e-05	0.000257	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—JUN—bone cancer	1.6e-05	0.000255	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MDM2—bone cancer	1.59e-05	0.000255	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MMP9—bone cancer	1.56e-05	0.00025	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—EGFR—bone cancer	1.55e-05	0.000249	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MMP9—bone cancer	1.55e-05	0.000248	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TP53—bone cancer	1.43e-05	0.000229	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TP53—bone cancer	1.43e-05	0.000229	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TP53—bone cancer	1.42e-05	0.000227	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TP53—bone cancer	1.39e-05	0.000222	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—JUN—bone cancer	1.39e-05	0.000222	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MMP9—bone cancer	1.35e-05	0.000216	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TP53—bone cancer	1.31e-05	0.000209	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—EGFR—bone cancer	1.26e-05	0.000202	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—EGFR—bone cancer	1.25e-05	0.000201	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—EGFR—bone cancer	1.09e-05	0.000174	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TP53—bone cancer	1.06e-05	0.000169	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TP53—bone cancer	1.05e-05	0.000169	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TP53—bone cancer	9.15e-06	0.000146	CbGpPWpGaD
